Comparison of Alnylam Pharmaceuticals Inc. (ALNY) and Akari Therapeutics Plc (NASDAQ:AKTX)

Since Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Akari Therapeutics Plc (NASDAQ:AKTX) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alnylam Pharmaceuticals Inc. 118 -0.32 110.54M -7.76 0.00
Akari Therapeutics Plc 2 0.00 10.35M -0.78 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals Inc. 93,582,797.16% -52.9% -37.1%
Akari Therapeutics Plc 557,050,592.03% -716.4% -158.5%

Volatility and Risk

Alnylam Pharmaceuticals Inc. has a beta of 2.43 and its 143.00% more volatile than Standard and Poor’s 500. Akari Therapeutics Plc’s 380.00% more volatile than Standard and Poor’s 500 which is a result of the -2.8 beta.

Liquidity

Alnylam Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 5.4 and 5.2 respectively. The Current Ratio and Quick Ratio of its competitor Akari Therapeutics Plc are 1.7 and 1.7 respectively. Alnylam Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Akari Therapeutics Plc.

Analyst Ratings

Recommendations and Ratings for Alnylam Pharmaceuticals Inc. and Akari Therapeutics Plc can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alnylam Pharmaceuticals Inc. 0 1 10 2.91
Akari Therapeutics Plc 0 0 0 0.00

Alnylam Pharmaceuticals Inc.’s upside potential currently stands at 16.94% and an $138.09 average target price.

Insider & Institutional Ownership

The shares of both Alnylam Pharmaceuticals Inc. and Akari Therapeutics Plc are owned by institutional investors at 98.5% and 3.4% respectively. Insiders held roughly 0.5% of Alnylam Pharmaceuticals Inc.’s shares. Competitively, insiders own roughly 57.08% of Akari Therapeutics Plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alnylam Pharmaceuticals Inc. 5.65% 36.71% 49.67% 75% 55.22% 69.74%
Akari Therapeutics Plc -3.88% 10.61% 3.66% -5.71% 10% 26.11%

For the past year Alnylam Pharmaceuticals Inc. was more bullish than Akari Therapeutics Plc.

Summary

Alnylam Pharmaceuticals Inc. beats Akari Therapeutics Plc on 7 of the 11 factors.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The companyÂ’s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.